Surgery Partners
SGRY
13.71
+0.30
+2.24%
Surgery Partners
US · SGRY
#2884 by market cap
Listed 2015
13.71
+0.30
+2.24%
Live - 5344 symbols - heartbeat 223s ago
· 2026-10-08 07:31
Pre-market
14.30
+4.30%
After-hours
13.71
0.00%
- Market cap
- 1.79B
- P/E (TTM)i
- -19.87
- P/Bi
- 1.07
- EPSi
- -0.61
- Div yieldi
- 0.00%
- 52W posi
- 19%
Reader sentiment
Are you bullish or bearish on SGRY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.77, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.24% YoY
Margins
- Gross margin
- 23.12%
- Operating margin
- 14.23%
- Net margin
- -2.35%
Key ratios & quality
- Enterprise valuei
- 5.30B
- Altman Z-Scorei
- 0.77
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.77B | 1.83B | 1.86B | 2.23B | 2.54B | 2.74B | 3.11B | 3.31B |
| Gross profit | 410.10M | 423.80M | 379.80M | 491.40M | 574.90M | 647.50M | 745.60M | 765.00M |
| Selling & admin expenses | 93.60M | 88.60M | 97.10M | 104.00M | 102.20M | 120.90M | 138.70M | 118.20M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 249.10M | 258.70M | 234.10M | 326.50M | 357.90M | 408.50M | 454.30M | 470.80M |
| Pretax profit | -69.20M | 54.60M | -18.80M | 81.20M | 110.30M | 135.00M | 147.10M | 116.90M |
| Tax | 26.40M | 9.50M | -20.10M | 10.50M | 23.30M | -300.00K | 134.60M | 18.00M |
| Net profit | -95.60M | 45.10M | 1.30M | 70.70M | 87.00M | 135.30M | 12.50M | 98.90M |
| Basic EPS | -5 | -2 | -3 | -1 | -1 | 0 | -1 | -1 |
| Diluted EPS | -4.96 | -2.29 | -3.19 | -1.12 | -0.59 | -0.09 | -1.33 | -0.61 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 776.00M | 826.20M | 821.50M | 885.00M | 810.90M | 848.90M |
| Gross profit | 161.90M | 195.60M | 195.30M | 212.20M | 160.20M | 190.20M |
| Selling & admin expenses | 36.00M | 36.10M | 22.40M | 23.70M | 39.30M | 36.30M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 89.60M | 121.30M | 135.10M | 124.80M | 84.10M | 116.50M |
| Pretax profit | -300.00K | 43.80M | 30.80M | 42.60M | -3.30M | 32.30M |
| Tax | 0 | -1.10M | 5.50M | 13.60M | -1.20M | 2.60M |
| Net profit | -300.00K | 44.90M | 25.30M | 29.00M | -2.10M | 29.70M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.30 | -0.02 | -0.18 | -0.12 | -0.28 | -0.12 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 588.30M | 525.50M | 801.50M | 946.10M | 921.00M | 895.00M | 1.12B | 1.15B |
| Cash & ST investments | 184.30M | 92.70M | 317.90M | 389.90M | 282.90M | 195.90M | 269.50M | 239.90M |
| Inventory | 43.40M | 46.30M | 56.40M | 61.10M | 71.40M | 75.20M | 88.40M | 96.60M |
| Total assets | 4.68B | 5.02B | 5.41B | 6.12B | 6.68B | 6.88B | 7.89B | 8.12B |
| Total current liabilities | 349.30M | 398.10M | 556.80M | 536.80M | 493.40M | 523.00M | 624.40M | 615.50M |
| Short-term debt | 55.60M | 93.30M | 103.60M | 100.50M | 99.30M | 110.90M | 142.40M | 142.00M |
| Long-term debt | 2.27B | 2.52B | 2.79B | 2.88B | 2.56B | 2.70B | 3.27B | 3.60B |
| Total liabilities | 2,891,500,000.00 | 3,319,500,000.00 | 3,789,800,000.00 | 3,817,800,000.00 | 3,399,200,000.00 | 3,514,800,000.00 | 4,254,800,000.00 | 4,592,900,000.00 |
| Total equity | 1.78B | 1.70B | 1.62B | 2.30B | 3.28B | 3.36B | 3.64B | 3.53B |
| Retained earnings | -247.00M | -315.70M | -431.80M | -502.70M | -557.30M | -569.20M | -737.30M | -815.20M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.07B | 1.11B | 1.10B | 1.15B | 1.08B | 1.13B |
| Cash & ST investments | 229.30M | 250.10M | 203.40M | 239.90M | 182.30M | 216.70M |
| Inventory | 88.10M | 87.30M | 92.30M | 96.60M | 100.50M | 98.80M |
| Total assets | 7.95B | 7.95B | 7.95B | 8.12B | 8.04B | 8.05B |
| Total current liabilities | 569.40M | 573.30M | 586.00M | 615.50M | 581.70M | 578.50M |
| Short-term debt | 143.50M | 149.60M | 144.30M | 142.00M | 142.60M | 143.50M |
| Long-term debt | 3.45B | 3.47B | 3.46B | 3.60B | 3.61B | 3.65B |
| Total liabilities | 4,362,700,000.00 | 4,375,900,000.00 | 4,393,600,000.00 | 4,592,900,000.00 | 4,560,800,000.00 | 4,581,300,000.00 |
| Total equity | 3.59B | 3.58B | 3.55B | 3.53B | 3.48B | 3.47B |
| Retained earnings | -775.00M | -777.50M | -800.20M | -815.20M | -851.10M | -866.10M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 144.60M | 129.50M | 246.90M | 87.10M | 158.80M | 293.80M | 300.10M | 274.30M |
| Depreciation & amortization | 67.40M | 76.50M | 94.80M | 98.80M | 114.80M | 118.10M | 152.60M | 176.00M |
| Free cash flow | 104.80M | 55.90M | 204.00M | 29.50M | 78.20M | 205.00M | 209.70M | 195.60M |
| Dividends paid | -7.80M | 0 | 0 | -5.10M | -- | -- | -- | -- |
| Stock buybacks / issuance | -2.00M | 0 | 0 | 581.80M | 882.90M | -- | -- | -- |
| Ending cash balance | 184.60M | 93.00M | 318.20M | 389.90M | 282.90M | 195.90M | 269.50M | 239.90M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 6.00M | 81.30M | 83.60M | 103.40M | 11.70M | 59.30M |
| Depreciation & amortization | 36.30M | 40.30M | 39.50M | 59.90M | 38.50M | 39.30M |
| Free cash flow | -16.70M | 57.90M | 63.80M | 90.60M | -4.30M | 37.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 229.30M | 250.10M | 203.40M | 239.90M | 182.30M | 216.70M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -44.96 | -31.51 | -75.46 | -13.48 | -3.54 | -0.60 | -8.90 | -4.45 |
| ROA %i | -5.12 | -2.28 | -2.98 | -1.41 | -0.85 | -0.18 | -2.28 | -0.97 |
| ROIC %i | -4.47 | 1.23 | -0.25 | 2.89 | 2.80 | 3.62 | -0.34 | 2.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -33.79 | -24.92 | -20.40 | -6.19 |
| EBIT margin %i | 4.39 | 12.75 | 9.84 | 13.58 | 13.59 | 11.96 | 11.20 | 11.77 |
| FCF / sales %i | 5.92 | 3.05 | 10.97 | 1.33 | 3.08 | 7.47 | 6.73 | 5.91 |
| Current ratioi | 1.68 | 1.32 | 1.44 | 1.76 | 1.87 | 1.71 | 1.79 | 1.87 |
| Quick ratioi | 1.41 | 1.05 | 1.26 | 1.53 | 1.50 | 1.32 | 1.36 | 1.37 |
| Debt / assetsi | 52.95 | 57.80 | 59.06 | 53.85 | 43.84 | 44.52 | 46.94 | 49.57 |
| LT debt / equityi | 598.29 | 946.02 | 2,675.87 | 293.30 | 141.65 | 148.49 | 198.97 | 226.68 |
| Interest coveragei | 0.53 | 1.31 | 0.91 | 1.37 | 1.47 | 1.70 | 1.73 | 1.43 |
| Revenue CAGR (3Y) %i | 22.66 | 16.93 | -- | 7.90 | 11.51 | 13.83 | 11.86 | 9.22 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 27.10 | -13.42 | -- | -34.46 | 11.84 | 0.16 | 92.28 | 35.74 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -10.43 | -9.75 | -9.45 | -4.45 | -4.44 | -5.18 |
| ROA %i | -2.59 | -2.34 | -2.21 | -0.97 | -0.95 | -1.11 |
| ROIC %i | -0.60 | -0.13 | 0.37 | 2.72 | 2.87 | 2.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 10.55 | 11.17 | 12.36 | 11.77 | 11.77 | 11.40 |
| FCF / sales %i | 5.46 | 5.42 | 5.90 | 5.91 | 6.22 | 5.57 |
| Current ratioi | 1.89 | 1.93 | 1.88 | 1.87 | 1.86 | 1.95 |
| Quick ratioi | 1.40 | 1.42 | 1.34 | 1.37 | 1.35 | 1.44 |
| Debt / assetsi | 48.60 | 48.76 | 48.72 | 49.57 | 50.09 | 50.41 |
| LT debt / equityi | 213.73 | 213.29 | 215.49 | 226.68 | 230.18 | 234.31 |
| Interest coveragei | 1.55 | 1.55 | 1.58 | 1.43 | 1.41 | 1.36 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Patient service revenues is the largest reported line at 97.31% of revenue, across 2 reported segments.
- The next-largest line, Other service revenues, is a distant second at 2.69% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Patient service revenues97.31%
Other service revenues2.69%
Quote time 2026-10-08 07:31:14 · For reference only, not investment advice and not tailored to your situation.